Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 10;32(12):1068–1085. doi: 10.1038/s41422-022-00746-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Scheme of BALB/c mouse immunization with HR121/Freund’s adjuvant at two-week intervals. Three groups of mice were immunized with different doses of HR121 plus CFA/IFA, and another two groups of mice were injected with CFA/IFA and PBS as negative controls. n = 6 per group. b Endpoint titers of bAbs to HR121. In another two groups of mice injected with adjuvant and PBS, the bAbs were not detectable (data not shown). c nAbs to authentic SARS-CoV-2 in the group immunized with 10 μg of HR121 at 7 days after the third immunization. d HR1-specific cellular immunity at 90 days after the third immunization. e HR121-specific humoral immunity at 90 days after the third immunization. f Scheme of BALB/c mouse immunization with HR121/Freund’s adjuvant at three-week intervals. g Endpoint titers of bAbs to HR121 at three-week intervals (colored in purple) compared with those at two-week intervals (colored in red). In b–e and g, each symbol represents a mouse. The bAbs and nAbs against HR121 in the controls are expected to be negative; therefore, we selected some of them to test, and the same is applied to the other figures. In b, c and g, data are presented as geometric mean ± geometric SD, and dashed lines represent the limit of quantification. In d and e, data are presented as median ± interquartile range. In b, d, e, and g, differences between each group are determined by one-way ANOVA.